A protein called PTX3 makes fatty liver damage worse during transplant surgery by activating immune cells to become overly inflammatory, according to a 2026 research article in International Immunopharmacology. Laboratory studies show that blocking PTX3 or using the drug ruxolitinib significantly reduced this damage and inflammation in fatty livers, suggesting a potential new treatment strategy for protecting donor organs during transplantation.

When doctors transplant a liver, the organ sometimes gets damaged during the procedure, especially if the liver is fatty. According to Gram Research analysis, scientists discovered that a protein called PTX3 makes this damage worse by triggering immune cells called macrophages to become overly aggressive and inflammatory. In studies using mouse models and lab-grown cells, blocking PTX3 or using a drug called ruxolitinib reduced this damage significantly. This discovery could lead to new treatments that protect fatty livers during transplantation, potentially improving survival rates for patients receiving donor organs.

Key Statistics

A 2026 research article published in International Immunopharmacology found that PTX3 protein expression increased markedly in fatty livers during transplant-related injury, and artificially increasing PTX3 in immune cells significantly aggravated liver damage and inflammation.

Laboratory studies showed that ruxolitinib, a drug that blocks the JAK1/STAT1 signaling pathway activated by PTX3, effectively reduced M1 macrophage polarization and alleviated inflammatory injury in fatty liver models.

Research demonstrated that PTX3 promotes M1 macrophage polarization through the JAK1/STAT1 pathway, a mechanism that was consistent across both mouse models of fatty liver and cultured cell systems.

The Quick Take

  • What they studied: How a protein called PTX3 damages fatty livers during transplant surgery by triggering harmful inflammation
  • Who participated: Laboratory mice with fatty livers and cultured immune cells and liver cells grown in dishes to mimic transplant conditions
  • Key finding: PTX3 protein levels increased dramatically during transplant-related injury in fatty livers, and blocking this protein or using a drug called ruxolitinib significantly reduced damage and inflammation
  • What it means for you: This research may lead to new medications that protect fatty livers during transplantation, potentially improving outcomes for patients receiving donor organs. However, these findings are from laboratory studies and need testing in humans before becoming standard treatment

The Research Details

Researchers used two main approaches to study this problem. First, they created fatty livers in mice using a high-fat diet, then temporarily cut off blood flow to the liver (mimicking what happens during transplant surgery) and restored it. They measured what happened to immune cells and liver damage. Second, they grew liver cells and immune cells together in dishes and exposed them to low oxygen followed by normal oxygen, simulating the injury that occurs during transplantation. This combination of animal and laboratory cell studies allowed researchers to understand both what happens in a living body and the specific molecular mechanisms involved.

Understanding exactly how fatty livers get damaged during transplant is crucial because fatty livers are more fragile and harder to transplant successfully. By identifying PTX3 as a key problem and finding that blocking it helps, researchers discovered a specific target for new treatments. This approach is more effective than trying general anti-inflammatory drugs because it targets the exact mechanism causing damage.

This study combined multiple research methods (animal models and cell cultures), which strengthens confidence in the findings. The researchers used specific genetic techniques to increase PTX3 levels and observed consistent harmful effects, then showed that blocking the pathway reversed the damage. However, because this is laboratory research, results may not directly translate to human patients. The study was published in a peer-reviewed journal, meaning other experts reviewed the work for quality.

What the Results Show

When researchers studied fatty livers during transplant-like injury, PTX3 protein levels increased dramatically compared to normal livers. When they artificially increased PTX3 in immune cells, liver damage got worse, with more inflammation and more liver cell death. The researchers identified the exact molecular pathway: PTX3 activates something called the JAK1/STAT1 signaling pathway, which tells immune cells to become aggressive and inflammatory. When they used a drug called ruxolitinib that blocks this pathway, the damage was significantly reduced, inflammation decreased, and fewer liver cells died.

The study showed that PTX3 specifically promotes a type of immune cell called M1 macrophages, which are aggressive and pro-inflammatory. These cells produce harmful chemicals called pro-inflammatory cytokines that damage liver tissue. The findings were consistent across both the mouse model and the laboratory cell culture system, suggesting the mechanism is reliable and reproducible.

Previous research showed that macrophage-driven inflammation is important in transplant injury, but the specific role of PTX3 was unclear. This study fills that gap by identifying PTX3 as a key regulator and showing that the JAK1/STAT1 pathway is the mechanism. The use of ruxolitinib, a drug already approved for other conditions, suggests a practical therapeutic approach that could be tested in clinical settings.

This research was conducted in laboratory settings using mice and cultured cells, not in human patients. Fatty livers in mice may not behave exactly like fatty livers in humans. The study did not test whether ruxolitinib works in actual transplant surgery in living animals, only in cell cultures. Additionally, the sample size and specific numbers of animals used were not detailed in the abstract. Before this treatment could be used in patients, it would need to be tested in larger animal studies and then human clinical trials.

The Bottom Line

This research suggests that blocking PTX3 or the JAK1/STAT1 pathway may protect fatty livers during transplantation. The drug ruxolitinib, which blocks this pathway, is a candidate for testing. However, these are laboratory findings with moderate confidence. Clinical trials in humans are needed before any new treatment recommendations can be made. Current transplant practices should not change based on this single study.

Liver transplant surgeons and patients awaiting liver transplants, particularly those with fatty livers, should follow this research. Patients with non-alcoholic fatty liver disease who may eventually need transplants should be aware of emerging protective strategies. Researchers studying transplant rejection and inflammation should consider PTX3 as a therapeutic target.

If this research leads to human trials, it typically takes 5 to 10 years for a new treatment to move from laboratory discovery to clinical use. Patients should not expect this therapy to be available immediately but may see it in clinical trials within 2 to 5 years if funding and regulatory approval proceed smoothly.

Frequently Asked Questions

What is PTX3 and why does it matter for liver transplants?

PTX3 is a protein that increases during transplant-related injury in fatty livers. It triggers immune cells to become overly aggressive and inflammatory, damaging the transplanted organ. Blocking PTX3 may protect fatty livers during transplantation.

Can ruxolitinib be used to protect fatty livers during transplant surgery?

Laboratory studies show ruxolitinib reduced damage in fatty liver models by blocking the PTX3 pathway. However, human clinical trials are needed before this drug can be recommended for transplant protection in patients.

How does a fatty liver become damaged during transplant surgery?

During transplant, the liver temporarily loses blood flow, then blood flow is restored. This causes injury and triggers immune cells to release harmful inflammatory chemicals. Fatty livers are more vulnerable to this damage than normal livers.

When will this PTX3 research lead to new treatments for transplant patients?

Laboratory discoveries typically take 5 to 10 years to become clinical treatments. Clinical trials may begin within 2 to 5 years if research funding and regulatory approval proceed. Patients should not expect this therapy immediately.

Does this research apply to people with fatty liver disease who haven’t had a transplant?

This research specifically addresses transplant-related injury in fatty livers. However, understanding PTX3’s role in liver inflammation may eventually help develop treatments for non-alcoholic fatty liver disease in general populations.

Want to Apply This Research?

  • For patients with fatty liver disease awaiting transplant, track liver function tests (ALT, AST, bilirubin levels) monthly and record any changes in fatigue or abdominal symptoms to monitor disease progression
  • Users can log daily diet choices, focusing on reducing saturated fats and refined carbohydrates, which are known to worsen fatty liver disease and may increase transplant risk
  • Set monthly reminders to review liver health markers with your doctor and track weight changes, as weight loss of 5 to 10 percent can improve fatty liver condition and potentially reduce transplant complications

This research is from laboratory studies in mice and cultured cells, not human patients. These findings do not constitute medical advice and should not change current transplant practices. Patients with fatty liver disease or those awaiting liver transplant should discuss these emerging findings with their transplant team and hepatologist. Ruxolitinib is not currently approved for liver transplant protection. Any new treatment based on this research would require extensive human clinical trials and regulatory approval before becoming standard medical practice. Always consult with qualified healthcare providers before making decisions about transplant care or treatment options.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: PTX3 aggravates ischemia-reperfusion injury in steatotic liver by promoting M1 macrophage polarization via activation of the JAK1/STAT1 pathway. , International immunopharmacology (2026). PubMed 42913198 | DOI
Topics
fatty liver transplant PTX3 protein liver transplant injury macrophage inflammation ruxolitinib JAK1/STAT1 pathway ischemia-reperfusion injury liver graft protection